elements
-live
Search elements, keywords, and sectors
🔎
Elements
Subjects
Papers
Communities
Lab
API & MCP
Pricing
Log in
Sign up
Home
/
Subjects
/
Levothyroxine
← Back to subjects
Current data, viewed at
Yearly
resolution.
Personal members see monthly resolution →
Keyword
keyword
Levothyroxine
RIS
0.001
(Research Intensity Score)
Papers
165
Top papers
Hypothyroidism
2022 · 331 citations
Hypothyroidism
2025 · 52 citations
2015 American Thyroid Association Management Guidelines for Adult Patients with Thyroid Nodules and Differentiated Thyroid Cancer: The American Thyroid Association Guidelines Task Force on Thyroid Nodules and Differentiated Thyroid Cancer
2015 · 16720 citations
ETA guidelines for the use of levothyroxine sodium preparations in monotherapy to optimize the treatment of hypothyroidism
2025 · 33 citations
Hypothyroidism in Context: Where We’ve Been and Where We’re Going
2019 · 451 citations
Newest papers
Sequential Amiodarone‐Induced Thyroid Dysfunction: From Myxedema Coma to Late‐Onset Type 1 Thyrotoxicosis After Drug Withdrawal
2026 · 1 citations
Stability-aware LSTM–MPC framework for personalized levothyroxine dosing in Hashimoto’s thyroiditis
2026
ĐẶC ĐIỂM LÂM SÀNG, CẬN LÂM SÀNG VÀ KẾT QUẢ ĐIỀU TRỊ NGOẠI TRÚ BỆNH NHÂN SUY GIÁP TẠI BỆNH VIỆN ĐA KHOA LỤC NAM, TỈNH BẮC NINH
2026
Mediterranean diet adherence and thyroid-related quality of life in women with Hashimoto thyroiditis: a multicenter cross-sectional study
2026
Case Report: Low-dose mitotane in a case of recurrent adrenocortical carcinoma: a 20-year clinical perspective
2026
A sample from the 100 top papers behind Levothyroxine.
Create a free account to browse them all →
Levothyroxine's history
Research intensity over time
Explore Levothyroxine's full history
Hover any year for its value and switch resolutions with a free account. Personal adds monthly detail and the historical-intensity (HRI) line.
Create a free account
Already have an account?
Log in
to explore the data.
Close ✕
Levothyroxine's papers
Ordered by current research-activity contribution.
Loading…
Close ✕
Read full text ↗
Share
Share on X
Share on Facebook
Share on LinkedIn
Copy link